CommercialCoverageHigh impact
08.00.66w, Bevacizumab (Avastin®) and Related Biosimilars For Oncologic Use
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Nov 26, 2025
We identified it
Jun 19, 2026
Summary
Policy 08.00.66w for Bevacizumab (Avastin®) and related biosimilars for oncologic use has been reissued effective November 26, 2025. This is a recent policy update that may contain changes to coverage criteria, prior authorization requirements, or billing guidelines for bevacizumab and its biosimilar alternatives in cancer treatment. Billing teams must review the full policy text to identify specific coverage changes, documentation requirements, and any new prior authorization workflows.
Action Required
By November 26, 2025: Billing team must obtain and review the complete policy text at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=11&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-00-66w to identify specific HCPCS codes, prior authorization requirements, and documentation standards for bevacizumab and biosimilar claims. Update billing system rules, prior authorization workflows, and provider communication materials accordingly. Identify all claims currently in process for bevacizumab administration and verify compliance with the new policy terms. Notify oncology providers of any changes to coverage criteria or documentation requirements. Failure to implement updates may result in claim denials or delays.